NHS wins legal fight with pharma over off-label Avastin - PMLiVE
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
More Medicare Musings: Why Lucentis is Worth the Price Tag - Eyedolatry
File:Bevacizumab label 01.jpg - wikidoc
Drug giants threaten NHS with legal action over cheaper drug that could save £84m a year | NHS | The Guardian
France wants Avastin used in place of Lucentis - PMLiVE
Avastin now available in UK for ovarian cancer | Pharmafile
PDF) Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Avastin - FDA prescribing information, side effects and uses
U.K. regulator supports off-label use of Avastin for serious eye condition
Doctors appeal to prescribe Avastin off-label | Pharmafile
Legal threat to NHS for using cheap drug Avastin | News | The Times
EU rules Avastin can be reimbursed for off-label use
MHRA clarifies position on off-label Avastin - PharmaTimes
Fake version cancer drug Avastin found in U.S. - New York Daily News
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open- label, phase 3 trial - The Lancet
EFPIA Files Complaint Against French Law Promoting Off-Label Avastin Use – Policy & Medicine
ABPI chief exec backs Novartis legal challenge to off-label Avastin - PMLiVE
Avastin, Lucentis & Zaltrap, Eylea - ppt download
Novartis' new macular degeneration drug has to compete against colon cancer drug Avastin. Why? < Pharma < 기사본문 - KBR
Avastin Lawsuits - Off-Label Use, Eye Infection, Blindness Risk
Avastin Injections Are Said to Cause Blindness - The New York Times
10. Avastin | FiercePharma
Avastin may fight early breast cancers in certain women | CTV News
Roche - Avastin (bevacizumab)
Immunotherapy Regimen Approved for Hepatocellular Carcinoma - MPR
FDA Says Avastin Not Safe or Effective for Patients With Breast Cancer
